Neuroendocrine Carcinomas Clinical Trial
Official title:
A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas Progressing After First-Line Platinum- Based Therapy
To assess the efficacy and safety of Temozolomide for second-line treatment of Neuroendocrine Carcinomas progressing after first-line Platinum-based therapy.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02820857 -
Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02695459 -
Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin
|
Phase 2 | |
Recruiting |
NCT06041516 -
Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
|
Phase 1 | |
Completed |
NCT02457273 -
Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients
|
Phase 2 | |
Recruiting |
NCT01203306 -
Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors
|
Phase 2 | |
Suspended |
NCT05337735 -
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
|
Phase 2 |